GeoVax, Inc., a privately held biotechnology company based in Atlanta, Georgia, recently announced that on September 28, 2006, it completed its merger with Dauphin Technology, Inc. (”Dauphin”), a publicly traded company based in Schaumburg, Illinois.

Upon closing the merger, Dauphin's name was changed to GeoVax Labs, Inc. (“GeoVax”). GeoVax' s common stock is now quoted on the NASDAQ OTCBB under the symbol DNTK.OB and for a period of time will continue trading on the Pink Sheets under the symbol DNTK.PK. GeoVax will announce its new stock symbol on its web site at www.geovax.com as soon as it is available.

Under the deal, according to the Atlanta Business Chronicle, Atlanta's Emory University, which now owns about 48 percent of the outstanding capital stock of GeoVax, would become the largest shareholder of GeoVax Labs Inc., owning about 31 percent of the new company's outstanding capital stock.

Donald Hildebrand, GeoVax CEO, would become the CEO of GeoVax Labs Inc.

GeoVax is a biotechnology company that develops, licenses and commercializes the manufacture and sale of human vaccines for diseases caused by Human Immunodeficiency Virus (HIV) and other infectious agents.

GeoVax initiated a planned series of four human clinical trials in April 06 with its DNA and MVA AIDS vaccines at several sites in the USA. The second trial of the series began in the last week of September. A previous human clinical trial with its DNA vaccine was satisfactorily completed.

GeoVax participated in the early-stage program of the Southeastern BIO Investor Forum 2002.